There are a few ways to help pinpoint the presence of<unk> . Newborn screening for<unk>  includes assaying dried blood cells for GALC enzyme activity and molecular analysis for evidence of GALC enzyme mutations. Infants displaying low enzyme activity and/or enzyme mutations should be referred for additional diagnostic testing and neurological examination. 0-5% GALC enzyme activity is observed in all symptomatic individuals with<unk> . High concentration of psychosine in dried blood spots may also be identified as a marker for<unk> . A 2011 study discovered that individuals with<unk> , more so in later-onset individuals, tend to have an abnormal increase in CSF protein concentration. The disease may be diagnosed by its characteristic grouping of certain cells (multinucleated globoid cells), nerve demyelination and degeneration, and destruction of brain cells. Special stains for myelin (e.g., luxol fast blue) may be used to aid diagnosis. New York, Missouri and Kentucky include<unk>  in the newborn screening panel. Indiana will start screening in 2020. Parents of newborns with a diagnosis of<unk>  can access online community support and resources below.
Krabbe disease
Foster Kennedy syndrome
Batten disease
Sandhoff disease
Stratton Parker syndrome
Warburg Micro syndrome
Fukuyama congenital muscular dystrophy
Dejerine–Sottas disease